Home
overview

As the fastest growing therapeutic segment, the market for pain medicines is set to soar, with an estimated growth rate of over 20% through 2006 and beyond. With both successes and failures in developing effective pain management drugs, the market has and will continue to undergo significant changes.

SMi’s 6th Annual Conference on Pain Therapeutics brings together proven leaders from industry and academia to discuss the latest innovations and commercial opportunities within the market. Addressing key and pertinent issues, this conference will demonstrate how to overcome both clinical and market unmet needs and will seek to address the main questions surrounding major bottlenecks in drug discovery. How can we improve target identification and validation? How well can experimental studies predict the outcome of clinical studies? What is the optimal study design for a new drug?

This important annual event will also explore P2 receptor involvement in chronic pain, the use of N-type calcium channel blockers, as a new class of drug, key challenges in the development of new analgesics and will provide an insight into emerging neuropathic pain therapeutics. Enhancing your knowledge and understanding of fundamental issues this conference will provide you with key advantages in a highly competitive market.

Gain an insight from the key industry leaders in the field including:

  • Dr Raymond Dionne, Senior Investigator & Chief, Pain & Neurosensory Mechanisms Branch, National Institute of Dental & Craniofacial Research, National Institutes of Health
  • Dr David Lee, Executive Vice President, Research & Development & Chief Scientific Officer, Endo Pharmaceuticals
  • Dr Stephen Cooper, Senior Vice President for Clinical & Medical Affairs, Wyeth Consumer Healthcare
  • Dr Stephen Donoghue, Vice President, Clinical Development, Europe, Elan Corporation
  • Professor Phil Skolnick, Chief Scientific Officer, DOV Pharmaceuticals
  • Dr Chas Bountra, Vice President & Head, Biology, GlaxoSmithKline
  • Franck Kiser, Vice President, Worldwide Drug Delivery Technologies, Cephalon
  • Dr Kathryn Rogers, Director, Neuroscience Discovery, Wyeth
  • Dr Mark Field, Associate Research Fellow-Translational Pharmacology Leader, Pfizer

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Praveen Anand

Praveen Anand, Professor, Clinical Neurology, Imperial College London, Hammersmith Hospital

9:10 ADVANCES IN PAIN THERAPEUTICS

David Lee

David Lee, Executive Vice President, Research & Development & Chief Scientific Officer, Endo Pharmaceuticals Inc

  • Assessing the pain therapeutics market
  • Current and future approaches to treatment
  • Successes and failures in developing pain management drugs
  • Tools and methods used in the development of more effective drugs
  • Challenges and unmet needs
  • Recent and future patent expirations for key drugs
  • Which areas require further investment for pain management?
  • 9:50 CHALLENGES IN DRUG DISCOVERY FOR NOVEL PAIN THERAPEUTICS

    Chas Bountra

    Chas Bountra, Vice President & Head, Biology, GlaxoSmithKline

  • How well do preclinical pharmacodynamic readouts translate into the clinic?
  • How can we identify targets fundamental to disease pathology?
  • How useful is localisation data?
  • How useful are knockouts?
  • 10:30 Morning Coffee

    10:50 UNDERSTANDING THE MECHANISMS OF PAIN

    Kathryn Rogers

    Kathryn Rogers, Director, Neuroscience Discovery, Wyeth

  • Measuring pain- methodologies, challenges and limitations
  • Difficulties in assessing pain in animals
  • How effective are these models at predicting efficacy in humans?
  • New models of chronic pain
  • 11:30 FROM PAIN RESEARCH TO PAIN TREATMENT

    Praveen Anand

    Praveen Anand, Professor, Clinical Neurology, Imperial College London, Hammersmith Hospital

  • The use of experimental human pain models in the development of treatment
  • Testing therapeutic regimes in patients with acute and chronic pain
  • How can experimental studies predict the outcome of clinical studies?
  • Lessons learned from failed clinical trials
  • New models for assessing pain
  • 12:10 Networking Lunch

    13:40 HOW DO PAIN INDICATIONS TRANSLATE INTO STUDY DESIGN?

    Peter Schüler

    Peter Schüler, Vice President, Medical Affairs, PRA International

  • What pain indications are of main research interest?
  • What options for study concepts are available?
  • The authorities’ perspectives
  • What do recent projects tell us?
  • Endpoint selection
  • Can we overcome the ‘diary endpoint dilemma’?
  • 14:20 TRANSLATIONAL PHARMACOLOGY IN PAIN

    Mark Field

    Mark Field, Associate Research Fellow - Translational Pharmacology Leader, Pfizer

  • Why we need a translational approach in pain
  • Outlining the opportunities for a translational approach
  • Key requirements from clinical pain research
  • Rethinking preclinical research with clinical outcomes
  • Current status of translational pharmacology
  • 15:00 THE OPTIMAL MODEL FOR EVALUATING ACUTE PAIN DRUGS

    Stephen Cooper

    Stephen Cooper, Senior Vice President, Clinical & Medical Affairs, Wyeth Consumer Healthcare

  • Characteristics for a sensitive pain model
  • The upside and downside of assay sensitivity
  • The optimal study design for a new drug
  • What the archival literature teaches us
  • 15:40 Afternoon Tea

    16:00 NO PAIN NO DEVELOPMENT GAIN

    John Connell

    John Connell, Head, Clinical Pharmadynamics, Medeval Limited

  • Can models make a molecule a medicine?
  • Can acute models reflect chronic states?
  • Capsaicin a putative neuropathic model
  • Are existing models able to detect novel pathway pharmacology?
  • 16:40 P2 RECEPTOR INVOLVEMENT IN CHRONIC PAIN

    Michael Jarvis

    Michael Jarvis, Project Leader & Associate Research Fellow, Pain Modulation, Neuroscience Research, Abbott Laboratories

  • Preclinical research – the role of P2X and P2Y in the modulation of chronic pain
  • Discovering small molecule anatagonists for P2X receptors
  • Valuable techniques in drug discovery – gene knockout, antisense and siRNA approaches
  • Efficacy of P2 receptor ligands in animal pain models
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Keith Foster

    Keith Foster, General Project Manager, Health Protection Agency

    9:10 NEUROPATHIC PAIN – A NEW FIELD TO EXPLORE

    Florian von Raison

    Florian von Raison, Medical Manager, Neurology, Pfizer France SARL

  • Definitions of Neuropathic Pain (NP): limits and challenges
  • Epidemiology of NP: who sees the patients? What is done?
  • Diagnostics tools: what’s new?
  • How to measure success of treatment
  • 9:50 EMERGING NEUROPATHIC PAIN THERAPEUTICS

    Nicos Sarantis

    Nicos Sarantis, Clinical Development Director, GW Pharmaceuticals

  • Cannabis has been used for the relief of pain for centuries
  • Use of cannabis for medical purposes declines as its misuse became the focus of attention
  • Recently developed cannabis-based medicines (CBMs) are made under strictly controlled quality systems ensuring consistent end products
  • Sativex is a CBM studied in the treatment of pain
  • The efficacy and safety of Sativex in the treatment of central and peripheral neuropathic pain will be presented
  • 10:30 Morning Coffee

    10:50 PERIPHERAL NERVOUS SYSTEM TARGETS FOR ACUTE AND CHRONIC PAIN

    Kazimierz Babinski

    Kazimierz Babinski, Vice President, Drug Development, PainCeptor Pharma Corporation

  • Benefits of peripheral vs central targets
  • Novel approaches under development
  • Importance of acid-sensing ion channels and NGF receptors in pain pathways
  • Advances in ASIC and NGF blockers in pain management
  • Building a portfolio of products
  • 11:30 N-TYPE CALCIUM CHANNEL BLOCKERS - A NEW CLASS OF DRUG

    Stephen Donoghue

    Stephen Donoghue, Vice President, Clinical Development, Europe, Elan Corporation

  • Understanding the mechanism of action -blocking the nerve channels responsible for producing pain
  • How effective is this drug in relieving severe chronic pain often caused by Cancer and HIV?
  • Differences between PRIALT and morphine
  • Drug delivery methodology
  • The latest clinical results
  • Achieving FDA approval
  • Getting the product to market
  • 12:10 Networking Lunch

    13:50 NARCOTIC ANALGESICS

    Vincent Hoffmann

    Vincent Hoffmann, Department of Anesthesiology and Pain Treatment Center, University Hospital of Antwerp

  • How do opioids work?
  • Dose titration and differences between clinical and laboratory pharmacology
  • Choosing the right opioid
  • Measuring efficacy- speed of onset and duration of effect
  • Current safety concerns
  • Reporting adverse events
  • Changing drug (opioid rotation) or changing route of administration
  • Opioids in non cancer pain
  • A combined approach to pain- the use of opioids with non opiods (tachykinins ,…)
  • 14:20 IMPROVING ANALGESIC DRUG DEVELOPMENT

    Raymond Dionne

    Raymond Dionne, Chief, Pain & Neurosensory Mechanims Branch, National Institutes of Health

  • Limitations of currently available analgesic drugs
  • Searching for new analgesics with greater efficacy and less morbidity
  • Advances in analgesic therapies
  • Improving drug development to improve pain management
  • Addressing unmet clinical needs
  • Novel approaches
  • 15:00 BICIFADINE- A BROAD SPECTRUM ANALGESIC

    Phil Skolnick

    Phil Skolnick, Chief Scientific Officer, DOV Pharmaceutical, Inc.

  • In vitro studies focusing on bicifadine’s mechanism of action
  • In vivo: exploration of analgesic activity pain models
  • Clinical studies describing safety and tolerability of bicifadine in normal volunteers
  • Clinical studies demonstrating analgesic efficacy in post-surgical pain
  • 15:40 Afternoon Tea

    16:00 NEUROIMAGING OF PAIN

    Irene Tracey

    Irene Tracey, Lecturer & Head, Pain Imaging Neuroscience Group, Oxford University

  • The current use of imaging in pain studies
  • Using imaging to study issues of pain perception
  • New developments in brain imaging- a better understanding of cortical and subcortical processes involved in pain perception and the establishment of chronic pain
  • Accelerating development in the area of pain imaging
  • Strategies for the use of imaging in drug discovery and development
  • 16:40 DRUG DELIVERY TECHNOLOGY

    Franck Kiser

    Franck Kiser, Vice President, Worldwide Drug Delivery Technology, Cephalon Inc.

  • Global unmet needs of the pain management market
  • Key market issues
  • Case studies of drug delivery solutions
  • Future potential applications
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    +

    Workshops

    Rational Design of Novel Analgesics for Neuropathic Pain
    Workshop

    Rational Design of Novel Analgesics for Neuropathic Pain

    Jurys Great Russell Street Hotel
    15th June 2005
    London, United Kingdom

    Jurys Great Russell Street Hotel

    16-22 Great Russell Street
    London WC1B 3NN
    United Kingdom

    Jurys Great Russell Street Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.